蜂胶对肠易激综合征患者生活质量及并发症影响的随机双盲安慰剂对照试验方案
BACKGROUND: Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS.…
要点
- 蜂胶含抗氧化、抗炎及益生元特性,可能通过降低炎症改善IBS严重程度。
- 主要结局为IBS严重程度改善,次要结局包括体重、腰围和生活质量。
核心结论
- 该试验旨在评估蜂胶补充对Rome IV诊断的成人IBS患者IBS严重程度、体重、腰围及生活质量的影响,假设蜂胶通过抗氧化、抗炎和益生元特性对IBS治疗有益。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局为从基线至干预第6周IBS严重程度的改善;次要结局包括体重、腰围和IBS生活质量的变化。
- 统计分析采用配对样本t检验或Mann-Whitney U检验进行组内比较,独立样本t检验或Wilcoxon秩和检验及卡方检验或Fisher精确检验进行组间比较,并使用ANCOVA计算多变量调整的平均效应。
临床怎么用
- 若试验验证假设,蜂胶补充可能成为IBS辅助治疗的新选择。
局限性
- 原文为研究方案,尚未提供疗效和安全性数据;单中心设计可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS. METHODS: This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired sample t test or Mann-Whitney U test for the within-group comparison and independent sample t test or Wilcoxon rank-sum and chi-square test or Fisher's exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test. DISCUSSION: We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020. https://en.irct.ir/trial/40983 SPONSOR: Tabriz University of Medical Sciences, Tabriz, Iran.
引用
- Miryan M, Alavinejad P, Abbaspour M, et al. Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial. Trials. 2020. PMID: 32758282. doi:10.1186/s13063-020-04615-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。